Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

Christian W. Keller; Tobias Ruck; Donal McHugh; Steffen Pfeuffer; Catharina C. Gross; Catharina Korsukewitz; Nico Melzer; Luisa Klotz; Sven G. Meuth; Christian Münz; Falk Nimmerjahn; Heinz Wiendl; Jan D. Lünemann

doi:10.1002/acn3.50935

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

Christian W. Keller, Tobias Ruck, Donal McHugh, Steffen Pfeuffer, Catharina C. Gross, Catharina Korsukewitz, Nico Melzer, Luisa Klotz, Sven G. Meuth, Christian Münz, Falk Nimmerjahn, Heinz Wiendl, Jan D. Lünemann

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.

Original language	English
Pages (from-to)	2586-2594
Number of pages	9
Journal	Annals of Clinical and Translational Neurology
Volume	6
Issue number	12
DOIs	https://doi.org/10.1002/acn3.50935
State	Published - 1 Dec 2019
Externally published	Yes

Access to Document

10.1002/acn3.50935

Cite this

@article{3f6e37140aee4ba1af3ee5a9a95ea6d6,

title = "Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis",

abstract = "Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.",

author = "Keller, {Christian W.} and Tobias Ruck and Donal McHugh and Steffen Pfeuffer and Gross, {Catharina C.} and Catharina Korsukewitz and Nico Melzer and Luisa Klotz and Meuth, {Sven G.} and Christian M{\"u}nz and Falk Nimmerjahn and Heinz Wiendl and L{\"u}nemann, {Jan D.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.",

year = "2019",

month = dec,

day = "1",

doi = "10.1002/acn3.50935",

language = "English",

volume = "6",

pages = "2586--2594",

journal = "Annals of Clinical and Translational Neurology",

issn = "2328-9503",

publisher = "John Wiley & Sons Inc.",

number = "12",

}

TY - JOUR

T1 - Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

AU - Keller, Christian W.

AU - Ruck, Tobias

AU - McHugh, Donal

AU - Pfeuffer, Steffen

AU - Gross, Catharina C.

AU - Korsukewitz, Catharina

AU - Melzer, Nico

AU - Klotz, Luisa

AU - Meuth, Sven G.

AU - Münz, Christian

AU - Nimmerjahn, Falk

AU - Wiendl, Heinz

AU - Lünemann, Jan D.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.

AB - Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.

UR - http://www.scopus.com/inward/record.url?scp=85074785109&partnerID=8YFLogxK

U2 - 10.1002/acn3.50935

DO - 10.1002/acn3.50935

M3 - Article

C2 - 31682087

AN - SCOPUS:85074785109

SN - 2328-9503

VL - 6

SP - 2586

EP - 2594

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

IS - 12

ER -

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis

Abstract

Access to Document

Fingerprint

Cite this